EXPERIENCE
JULY 1994 - PRESENT
BURKE PHARMACEUTICAL RESEARCH
Clinical Research Coordinator
3633 Central Avenue, Suite I
Hot Springs, AR 71913
(501) 620-4449
JOB DESCRIPTION
Efficiently coordinate and conduct clinical activities, including
participant recruitment and screening, data specimen collection
and study medication dispensation, according to protocol.
Develop and maintain complete and accurate federal regulatory
document files and study patient case histories.
EDUCATION / MEMBERSHIPS
Graduate of Hot Springs High School
University of Central Arkansas
Nine years business administration in medical field
Six years experience medical coding and terminology
Experienced Research Study Coordinator
DIA - Drug Information Association, July 2001
(ACRP) Association of Clinical Research Professionals
Certified in CPR Infants & Adults - Current
CLINICAL TRIALS
Phase I – Nasal Spray Treatment for Pediatric Allergic
Rhinitis
Phase I – I.V. Treatment for Moderate to Severe Plaque
Psoriasis
Phase II – Topical Treatment Plaque Psoriasis
Phase II – Topical Treatment for Scalp Psoriasis in Adolescent
Patients
Phase II – Infusion Treatment for Severe Plaque Psoriasis
Phase II – Topical Treatment for Genital Herpes
Phase II – Oral Treatment for Androgenetic Alopecia
Phase II – Topical Treatment for Plaque Psoriasis
Phase II – Oral Treatment for Plaque Psoriasis
Phase III – Topical Treatment Acne Vulgaris
Phase III – Topical Treatment for Actinic Keratosis
Phase III – Topical Treatment for Mild to Moderate Pediatric
Atopic Dermatitis
Phase III – Topical Treatment for Moderate to Severe
Atopic Dermatitis
Phase III – Topical Treatment for Fingernail Onychomycosis
Phase III – Topical Treatment for Tinea Pedis
Phase III – Topical Treatment for Plaque-Type Psoriasis
Phase III – Injection Treatment for Moderate to Severe
Plaque Psoriasis
Phase III – Topical Treatment for Plaque-Type Psoriasis
Phase III – Injection Treatment for Moderate to Severe
Plaque Psoriasis
Phase III – I.V. Treatment for Subjects with Moderate
to Severe Plaque Psoriasis
Phase III – Topical Treatment for Pediatric Atopic Dermatitis
Phase III – Topical Treatment for Actinic Keratosis
Phase III – Topical Treatment for Atopic Dermatitis
Phase III – Topical Treatment of Plaque Psoriasis in
Adult Patients
Phase III – Study of Topical Treatment for Tinea Versicolor
in Adult Patients
Phase III – I.V. Treatment for Subjects with Moderate
to Severe Psoriasis in Adult Patients
Phase III – I.M. Treatment for Patients with Moderate
to Severe Psoriasis
Phase III – Topical Treatment for Tinea Cruris in Adult
Patients
Phase III – Topical Treatment for Skin Infections
Phase III – Topical Treatment for Moderate to Severe
Scalp Psoriasis in Adult Patients
Phase III – Topical Treatment for Actinic Keratosis
Phase III – Topical Treatment for Basal Cell Carcinoma
Phase III – Topical Treatment for Onychomycosis
Phase III – Intralesional Treatment for Plaque Psoriasis
Phase III – Topical Treatment for Superficial Basal Cell
Carcinoma
Phase III – Topical Treatment for Atopic Dermatitis in
Pediatric Patients
Phase III – Topical Treatment for Plaque Psoriasis
Phase IIIB – Oral Treatment for Herpes Labialis
Phase IV – Oral Treatment for Genital Herpes
Phase IV – Topical Treatment for Identical Twins with
Actinic Damage
Phase IV – Oral Treatment for Identical Twins with Male
Pattern Hair Loss
Phase IV – IV Treatment for subjects with Moderate to
Severe Psoriasis
A Data Collection Study for Psoriasis and Healthy Volunteers
Effect of Finasteride on Identical Male Twins with Male Pattern
Baldness.
THE ABOVE CLINICAL TRIALS WERE CONDUCTED BY THE FOLLOWING
COMPANIES:
3M Pharmaceuticals
Abgenix
Allergan
Altana
Amgen
Astellas
Barrier
Bertek Pharmaceuticals
Biogen
Burke Pharmaceutical Research
Centocor
Connetics
Dermik Pharmaceuticals
Dow Pharmaceutical
Fujisawa
Galderma Laboratories
Genomics
Glaxo/SmithKline
Glaxo/Welcome
Healthpoint
Icon
Medicis Pharmaceuticals
Merck Pharmaceuticals
Novartis
Spear Pharmaceutical
Teva Pharmaceutical
Therapeutics/Ferndale
Watson Labs
Xoma
INDICATIONS
Acne Rosacea
Acne Vulgaris
Actinic Damage
Actinic Keratosis
Allopecia
Atopic Dermatitis
Basal Cell Carcinoma
Genital Herpes
Herpes Labialis
Lyme Disease
Male Pattern Hair Loss
Mild to Moderate Psoriasis
Onychomycosis
Pediatric Atopic Dermatitis
Psoriatic Arthritis
Severe Plaque Psoriasis
Skin Infection
Sun Damaged Skin
Tinea Versicolor
Verrucae
MEETINGS / SEMINARS
Altana Pharmaceutical Investigator Meeting, June 24-26, 2005 – Punta
Cana, Dominican Republican
Barrier Pharmaceutical Investigator Meeting, May 13-14, 2005 – Washington,
DC
Teva Pharmaceutical Investigator Meeting, April 29-30, 2005 – Scottsdale,
AZ
QUATRx Investigator Meeting, August 27-28, 2004 – Detroit,
MI
Serono Investigator Meeting, August 21-22, 2004 – Rockland,
MA
Dow Pharmaceutical Investigator Meeting, March 5-6, 2004 – San
Diego, CA
Xoma Pharmaceutical Investigator Meeting, January 9-11, 2004 – Sonoma,
CA
Novartis Investigators Meeting for Atopic Dermatitis, October
19-23, 2003 – Monte Carlo, Monaco
Fujisawa Investigator Meeting for Mild to Moderate Psoriasis,
October 10-12, 2003 – Chicago, IL
Novaritis Investigator Meeting for Genital Herpes and Herpes
Labialis, September 29-31, 2003 – Los Angeles, CA
Centocor Pharmaceutical Investigator Meeting for Moderate to
Severe Psoriasis, September 18-21, 2003, Orlando, FL
Dow Pharmaceutical Rosacea Lesion Count Training, July 11,
2003 – Dallas, TX
Altana Pharmaceutical Investigator Meeting, April 3-7, 2003 – St.
Thomas
Dow Pharmaceutical Investigator Meeting, January 15-17, 2003 – Las
Vegas, NV
Biogen Investigator Meeting, 22-26, 2002 – Boston, MA
Fujisawa Electronic Data Entry Meeting, June 12-14, 2002 – Chicago,
IL
Association of Clinical Research Professionals – ACRP
Winter Symposium, February 15-16, 2002 – St. Petersburg,
FL
Watson Laboratory Investigator’s Meeting Onychomycosis,
September 28-29, 2001 – Dallas, Texas
Drug Information Association – DIA Meeting: Clinical
Research Associates, December 3-6, 2000 – Albuquerque,
NM
Bertek Investigator’s Meeting: Tinea, August 15-16, 1999 – Miami,
FL
America Academy of Dermatology – AAD Annual Meeting,
February 21-25, 1999 – New Orleans, LA
American Academy of Dermatology – AAD Annual Meeting,
February 27- March 4, 1998 – Orlando, FL
